The Germ Cell Tumour Group of the French Society of Childhood Cancer has issued updated national therapeutic recommendations for extracranial malignant non-seminomatous germ cell tumours in children and adolescents, following completion of the TGM13-NS protocol.
These tumours are about 3% of childhood cancers, with a bimodal age distribution - one peak in early childhood and a second after puberty extending into adulthood. Prognosis on the Franco-Belgian TGM95 and TGM13-NS protocols has been excellent, and the direction of successive revisions has been de-escalation: surgery aiming at oncological control while preserving organ function where possible, with platinum-based chemotherapy given by risk group and with cycle numbers progressively reduced to limit late toxicity.
Risk stratification uses tumour stage and site, initial marker levels, and patient age. The recommendation that travels furthest is organisational rather than pharmacological: adolescents should be managed jointly by paediatric and adult oncology teams, and enrolled in trials wherever possible, because this is a rare cancer whose evidence base depends on it.
This is a national guideline, not a regulatory approval or a licensing change. Its relevance outside France is the framework - risk-stratified de-escalation and the explicit handling of the adolescent and young adult group, who in most systems, India included, fall between paediatric and adult services and are treated by whichever team happens to receive them. Marker-based risk stratification requires reliable alpha-fetoprotein and beta-hCG assays with age-appropriate reference ranges, which is the practical prerequisite anywhere.
- Measure alpha-fetoprotein and beta-hCG before any intervention - the levels drive risk stratification
- Use age-appropriate alpha-fetoprotein reference ranges in infants; adult ranges will mislead
- Agree in advance which team leads for an adolescent, rather than defaulting to who admitted them
- Prioritise organ-preserving surgery where oncological control allows
- This is a French national guideline, not a regulatory action, and carries no licensing change
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free